#Japan #Tokyo #Clinical Trials #Innovacell #ICEF15

Innovacell Secures FDA Approval for ICEF15 Clinical Trial

On July 2, 2026, Innovacell Co., Ltd., announced that it has completed the FDA's IND review process for the ICEF15 international Phase III clinical trial, known as the Fidelia study. This achievement allows the company to officially include US facilities and patients in their ongoing research, which is currently being carried out across Japan and Europe.

The ICEF15 clinical trial represents a significant advancement in addressing treatment options for patients suffering from urge incontinence, a condition where individuals experience involuntary loss of bowel control. It is estimated that about 5 million people in Japan alone are affected by this condition (source: Japan Society of Coloproctology). According to a paper published in specialized journals (Akimura et al., "A Survey Report on the Current State of Urge Incontinence Management in Japan", Japan Journal of Coloproctology 65:101-108, 2012), over 51% of patients report urge-related symptoms.

Currently, patients with urge urinary incontinence often undergo invasive surgical treatments, such as anal sphincteroplasty or sacral nerve stimulation, when conservative therapies yield insufficient improvements. However, these existing surgical options can present high levels of invasiveness and may yield inadequate results. In contrast, ICEF15 seeks to offer a less invasive and potentially more effective treatment alternative.

The Fidelia trial represents the final phase of clinical development for ICEF15, involving a randomized double-blind placebo-controlled study across 11 countries in Europe and Japan. A total of 290 patients will be equally allocated to either the trial group receiving the investigational drug or a placebo, with the primary endpoint evaluating changes in incontinence frequency at 12 months post-treatment. As of June 30, 2026, 250 patients have already been enrolled, marking an impressive 86% progress towards the target.

The completion of the FDA review enables Innovacell to pursue this study as part of a global Phase III trial, further solidifying its position in the largest pharmaceutical market in the world. Preparations to involve multiple US facilities in the Fidelia trial are already underway, and Innovacell plans to submit the additional documentation requested by the FDA within the designated timeframe. The company aims to complete patient enrollment for the Fidelia trial, including US participants, by the end of 2026.

This development milestone aligns with Innovacell's broader strategy of advancing the global deployment of ICEF15. Notably, it is relatively uncommon for biotech companies to conduct their own Phase III clinical trials that incorporate a large number of patients, particularly one that spans major global markets such as the US, Europe, and Japan. Since its inception, Innovacell has emphasized global development and business expansion as a key strategic direction; the recent US inclusion in the Fidelia study highlights this commitment.

For more information about the Fidelia trial, you can visit ClinicalTrials.gov NCT04976153.

About Innovacell Co., Ltd.

Founded in 2021 in Japan, Innovacell originated from a spin-off company focused on regenerative medicine from the Medical University of Innsbruck in Austria. Innovacell aims to enhance people's health and quality of life through the commercialization of cell therapy and regenerative medicine. The group is dedicated to researching and developing regenerative medicine products aimed at treating various types of incontinence, including urge and overflow incontinence. Currently, ICEF15 is being pushed as a potential core product in Innovacell's pipeline, directing its efforts towards addressing the fundamental treatment needs of patients suffering from urge incontinence.